Genmab A/S
GMAB
$20.25
$0.050.25%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 33.98% | 18.63% | 27.96% | 47.73% | -2.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.98% | 18.63% | 27.96% | 47.73% | -2.63% |
| Cost of Revenue | 164.77% | 248.69% | 793.49% | -- | -- |
| Gross Profit | 30.43% | 14.71% | 24.08% | 41.14% | -5.21% |
| SG&A Expenses | 32.38% | 1.49% | 6.75% | 28.11% | 6.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.37% | 14.04% | 31.11% | 39.73% | 25.25% |
| Operating Income | 28.17% | 26.89% | 22.16% | 94.12% | -29.57% |
| Income Before Tax | 254.10% | -35.04% | 24.00% | 551.93% | 85.03% |
| Income Tax Expenses | -179.13% | -19.24% | 97.78% | 605.59% | 450.86% |
| Earnings from Continuing Operations | 441.45% | -39.29% | 4.15% | 537.62% | 43.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 441.45% | -39.29% | 4.15% | 537.62% | 43.74% |
| EBIT | 28.17% | 26.89% | 22.16% | 94.12% | -29.57% |
| EBITDA | 30.39% | 27.22% | 22.31% | 84.73% | -29.54% |
| EPS Basic | 456.87% | -37.55% | 5.46% | 538.77% | 43.62% |
| Normalized Basic EPS | 332.02% | -37.24% | 34.21% | 876.95% | 72.27% |
| EPS Diluted | 457.77% | -37.42% | 5.67% | 539.32% | 43.77% |
| Normalized Diluted EPS | 332.53% | -37.10% | 34.47% | 877.77% | 72.43% |
| Average Basic Shares Outstanding | -2.77% | -2.77% | -1.24% | -0.18% | 0.08% |
| Average Diluted Shares Outstanding | -2.88% | -2.99% | -1.43% | -0.26% | -0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
